Literature DB >> 24976941

Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors.

Sebastian Trousil1, Laurence Carroll1, Andrew Kalusa1, Ola Aberg1, Maciej Kaliszczak1, Eric O Aboagye1.   

Abstract

Choline kinase alpha is hyperactivated in many solid tumours and regulates malignant progression, making it a promising cancer drug target. The successful design and synthesis of novel inhibitors with high cellular activity are described.

Entities:  

Year:  2013        PMID： 24976941      PMCID： PMC4071626          DOI： 10.1039/C3MD00068K

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  16 in total

Review 1.  Choline: an essential nutrient for humans.

Authors:  S H Zeisel
Journal:  Nutrition       Date:  2000 Jul-Aug       Impact factor: 4.008

2.  Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors.

Authors:  Belén Rubio-Ruíz; Ana Conejo-García; Pablo Ríos-Marco; María Paz Carrasco-Jiménez; Josefa Segovia; Carmen Marco; Miguel A Gallo; Antonio Espinosa; Antonio Entrena
Journal:  Eur J Med Chem       Date:  2012-02-03       Impact factor: 6.514

3.  Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.

Authors:  Nada M S Al-Saffar; Helen Troy; Ana Ramírez de Molina; Laura E Jackson; Basetti Madhu; John R Griffiths; Martin O Leach; Paul Workman; Juan C Lacal; Ian R Judson; Yuen-Li Chung
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

4.  Elucidation of human choline kinase crystal structures in complex with the products ADP or phosphocholine.

Authors:  Enrico Malito; Nikolina Sekulic; Wei Cun See Too; Manfred Konrad; Arnon Lavie
Journal:  J Mol Biol       Date:  2006-09-03       Impact factor: 5.469

5.  Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells.

Authors:  E O Aboagye; Z M Bhujwalla
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

6.  Balance of human choline kinase isoforms is critical for cell cycle regulation: implications for the development of choline kinase-targeted cancer therapy.

Authors:  Jens Gruber; Wei Cun See Too; Mun Teng Wong; Arnon Lavie; Theresa McSorley; Manfred Konrad
Journal:  FEBS J       Date:  2012-04-16       Impact factor: 5.542

7.  Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography.

Authors:  Timothy H Witney; Israt S Alam; David R Turton; Graham Smith; Laurence Carroll; Diana Brickute; Frazer J Twyman; Quang-Dé Nguyen; Giampaolo Tomasi; Ramla O Awais; Eric O Aboagye
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

Review 8.  Protein kinase C and other diacylglycerol effectors in cancer.

Authors:  Erin M Griner; Marcelo G Kazanietz
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

9.  Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.

Authors:  Ana Ramírez de Molina; Jacinto Sarmentero-Estrada; Cristóbal Belda-Iniesta; Miquel Tarón; Victor Ramírez de Molina; Paloma Cejas; Marcin Skrzypski; David Gallego-Ortega; Javier de Castro; Enrique Casado; Miguel Angel García-Cabezas; Jose Javier Sánchez; Manuel Nistal; Rafael Rosell; Manuel González-Barón; Juan Carlos Lacal
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

10.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.

Authors:  Ana Ramírez de Molina; Ruth Gutiérrez; Maria Angeles Ramos; José María Silva; Javier Silva; Félix Bonilla; José Javier Sánchez; Juan Carlos Lacal
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867
View more
  6 in total

1.  A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.

Authors:  A Estévez-Braun; A G Ravelo; E Pérez-Sacau; J C Lacal
Journal:  Clin Transl Oncol       Date:  2014-12-04       Impact factor: 3.405

Review 2.  Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.

Authors:  Sean P Arlauckas; Anatoliy V Popov; E James Delikatny
Journal:  Prog Lipid Res       Date:  2016-04-09       Impact factor: 16.195

3.  Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics.

Authors:  Yunqing Li; Marianna Inglese; Suraiya Dubash; Chris Barnes; Diana Brickute; Marta Costa Braga; Ning Wang; Alice Beckley; Kathrin Heinzmann; Louis Allott; Haonan Lu; Cen Chen; Ruisi Fu; Laurence Carroll; Eric O Aboagye
Journal:  Pharmaceutics       Date:  2021-08-12       Impact factor: 6.321

4.  Biological Evaluation of New Thienopyridinium and Thienopyrimidinium Derivatives as Human Choline Kinase Inhibitors.

Authors:  Pilar María Luque-Navarro; Elena Mariotto; Marco Ballarotto; Gianluca Rubbini; Francisco José Aguilar-Troyano; Alberto Fasiolo; Archimede Torretta; Emilio Parisini; Antonio Macchiarulo; Alejandro Laso; Carmen Marco; Giampietro Viola; María Paz Carrasco-Jimenez; Luisa Carlota López-Cara
Journal:  Pharmaceutics       Date:  2022-03-27       Impact factor: 6.525

5.  Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1).

Authors:  Santiago Schiaffino-Ortega; Eleonora Baglioni; Elena Mariotto; Roberta Bortolozzi; Lucía Serrán-Aguilera; Pablo Ríos-Marco; M Paz Carrasco-Jimenez; Miguel A Gallo; Ramon Hurtado-Guerrero; Carmen Marco; Giuseppe Basso; Giampietro Viola; Antonio Entrena; Luisa Carlota López-Cara
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

6.  The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.

Authors:  Sebastian Trousil; Maciej Kaliszczak; Zachary Schug; Quang-De Nguyen; Giampaolo Tomasi; Rosy Favicchio; Diana Brickute; Robin Fortt; Frazer J Twyman; Laurence Carroll; Andrew Kalusa; Naveenan Navaratnam; Thomas Adejumo; David Carling; Eyal Gottlieb; Eric O Aboagye
Journal:  Oncotarget       Date:  2016-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.